PD-L1 is upregulated in breast cancer, and the up-regulated expression is associated with clinicopathological features of breast cancer, such as large tumor size, high tumor grade, lack of hormone receptor expression, and HER-2 positivity (53). Here, ERBB2 is linked to breast carcinoma.